When a person faces a cancer diagnosis, their physical strength becomes a critical part of the battle. New research highlights how muscle loss, or sarcopenia, plays a significant role in how patients handle treatment. The study looked at 59 different analyses to see how muscle mass affects those undergoing surgery or first-line non-surgical therapies.
For those undergoing surgery, having low muscle mass was linked to shorter overall survival and a higher risk of complications after the procedure. For patients receiving non-surgical treatments, including immunotherapy, lower muscle mass was associated with poorer progression-free survival and worse overall outcomes. In every category measured, less muscle seemed to make the journey harder.
While these results show a clear link between muscle health and patient outcomes, it is important to note that the evidence for many of these findings is currently rated as low or very low certainty. This means while the trend is consistent across different cancer types, more high-quality data is needed to fully understand the impact.
